ArticleAdvanced materials interfaces2021
Graphene-Based Femtogram-Level Sensitive Molecularly Imprinted Polymer of SARS-CoV-2.
Article in Advanced materials interfaces, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 34 citations in OpenAlex.
- Surface-confined FRET nanoplatform printedRSC advances · 2026Article
- Recent Advances in Quantum Dot-Based Lateral Flow Immunoassays for the Rapid, Point-of-Care Diagnosis of COVID-19.Biosensors · 2023Review
- Carbon-based biosensors: Next-generation diagnostic tool for target-specific detection of SARS-CoV-2 (COVID-19).Talanta open · 2023Article
- Molecularly Imprinted Polymer-Based Electrochemical Sensors for the Diagnosis of Infectious Diseases.Biosensors · 2023Review
- Electrochemical and Bioelectrochemical Sensing Platforms for Diagnostics of COVID-19.Biosensors · 2023Review
- Editorial: Advanced nanotechnological detection and drug delivery configurations.Frontiers in pharmacology · 2023Article
- Ice-templated synthesis of multicomponent porous coatings via vapour sublimation and deposition polymerization.Materials today. Bio · 2022Article
- Evaluation of electropolymerized molecularly imprinted polymers (E-MIPs) on disposable electrodes for detection of SARS-CoV-2 in saliva.Analytica chimica acta · 2022Article
- Molecularly Imprinted Polymer-Based Sensors for SARS-CoV-2: Where Are We Now?Biomimetics (Basel, Switzerland) · 2022Review
- Biosensors for the Determination of SARS-CoV-2 Virus and Diagnosis of COVID-19 Infection.International journal of molecular sciences · 2022Review
- Graphene-Based Femtogram-Level Sensitive Molecularly Imprinted Polymer of SARS-CoV-2.Advanced materials interfaces · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapid distribution of viral-induced diseases and weaknesses of common diagnostic platforms for accurate and sensitive identification of infected people raises an urgent demand for the design and fabrication of biosensors capable of early detection of viral biomarkers with high specificity. Accordingly, molecularly imprinted polymers (MIPs) as artificial antibodies prove to be an ideal preliminary detection platform for specific identification of target templates, with superior sensitivity and detection limit (DL). MIPs detect the target template with the "lock and key" mechanism, the same as natural monoclonal antibodies, and present ideal stability at ambient temperature, which improves their practicality for real applications. Herein, a 2D MIP platform consisting of decorated graphene oxide with the interconnected complex of polypyrrole-boronic acid is developed that can detect the trace of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen in aquatic biological samples with ultrahigh sensitivity/specificity with DL of 0.326 and 11.32 fg mL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.